NFKB1 and metabolic syndrome: LPS interacts with Toll-like receptors (TLRs) and enhances the NFκB signaling pathway, leading to a low-grade of chronic inflammation that provokes the progression of metabolic syndrome towards more advanced cardiometabolic disorders [62].